ADMA News and Press, ADMA Biologics Inc From 03/24/22

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profitability for Full Year 2021 Driven by Greater Market Penetration of Higher-Margin Product Mix Completed $175 Million Debt Refinancing with Hayfin Capital Management,...

ADMA, BEAT, CLVR, CODX, CURI, HNST, OTCQB:IGXT, JOBY, LFC, MAXN, NIO, ONL, OSS, SGLB, TMC For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close

ADMA Biologics (NASDAQ:ADMA) is scheduled to announce Q4 earnings results on Thursday, March 24th, after market close. The consensus EPS Estimate is -$0.09 (+55.0% Y/Y) and the consensus Revenue Estimate is $21.77M (+55.9% Y/Y). For further details see: ADMA Biologics Q4 2021 Earnings P...

RAMSEY, N.J. and BOCA RATON, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived b...

ADMA Biologics (NASDAQ:ADMA) received U.S. FDA approval for its 5th ADMA BioCenters plasma collection facility in Conyers, Georgia. The facility began operations and initiated source plasma collection in Q3 of 2021. The facility is now FDA-approved to collect and introduce into interstate com...

FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by year-end 2023 RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., March 07, 202...

Adma Biologics (NASDAQ:ADMA) activist holder Caligan Partners is said to be supportive of the company's ongoing strategic review. Adma rose 1.5.%. The activist would support a sale of the company for at least $3/share, according to a Dealreporter item, which cited sources familiar. Poten...

Ready to make 2022 your best year yet but confused on how to make money the way the stock market is today? Some are calling this the “Year of the Active Trader,” and for a good reason. With broad sector stocks up one day and down the next, a long-term approach to trading is mo...

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception Full Year 2021 Preliminary Unaudited Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Compa...

RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, ...